Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Assets Average (2019 - 2025)

Silence Therapeutics' Assets Average history spans 7 years, with the latest figure at $139.1 million for Q4 2025.

  • On a quarterly basis, Assets Average fell 72.82% to $139.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $139.1 million, a 72.82% decrease, with the full-year FY2025 number at $167.0 million, up 3.72% from a year prior.
  • Assets Average hit $139.1 million in Q4 2025 for Silence Therapeutics, down from $156.0 million in the prior quarter.
  • Over the last five years, Assets Average for SLN hit a ceiling of $773.2 million in Q3 2024 and a floor of $139.1 million in Q4 2025.
  • Historically, Assets Average has averaged $392.2 million across 5 years, with a median of $424.2 million in 2022.
  • Biggest five-year swings in Assets Average: surged 127.69% in 2021 and later crashed 79.82% in 2025.
  • Tracing SLN's Assets Average over 5 years: stood at $262.4 million in 2021, then surged by 88.86% to $495.5 million in 2022, then dropped by 3.94% to $476.0 million in 2023, then increased by 7.54% to $511.9 million in 2024, then crashed by 72.82% to $139.1 million in 2025.
  • Business Quant data shows Assets Average for SLN at $139.1 million in Q4 2025, $156.0 million in Q3 2025, and $175.3 million in Q2 2025.